Raritan, NJ, United States of America

Xiaojie Li

This inventor holds 12 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Janssen Pharmaceutica Nv, J & J Pharmaceutical Research & Development, LLC., Ortho-Mcneil Pharmaceutical Corp.. Active years: 2008-2016.


% Patents Active = 16.7



Average Co-Inventor Count = 3.0

ph-index = 4

Forward Citations = 57(Granted Patents)


Location History:

  • Green Brook, NJ (US) (2008)
  • Raritan, NJ (US) (2008 - 2016)

Company Filing History:


Years Active: 2008-2016

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Xiaojie Li

Introduction

Xiaojie Li is a prominent inventor based in Raritan, NJ (US), known for his significant contributions to the field of pharmaceutical sciences. With a total of 12 patents to his name, he has made remarkable advancements in the development of novel therapeutic compounds.

Latest Patents

Among his latest patents are the "Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators." This invention is directed towards novel tetracyclic heteroatom containing derivatives, which are pharmaceutical compositions that can be utilized in the treatment of disorders mediated by one or more sex steroid hormone receptors. The processes for their preparation are also included in this innovative work.

Career Highlights

Xiaojie Li has worked with notable companies such as Janssen Pharmaceutica and Ortho-McNeil Pharmaceutical Corporation. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Some of his coworkers include Xuqing Zhang and Zhihua Sui, who have collaborated with him on various projects, enhancing the scope and impact of their research.

Conclusion

Xiaojie Li's innovative work and dedication to advancing pharmaceutical sciences have established him as a key figure in the field. His contributions continue to influence the development of new therapeutic options for patients.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…